2026-06-17

Bladder

One bladder-preservation signal: IO induction layered ahead of chemoRT, no randomised comparator vs cystectomy or CRT alone.

INDIBLADE

ForStage II/III muscle-invasive bladder, cT2-4aN0-2

TL;DR2-yr bladder-intact EFS 78% (0.67-0.9), OS 96% (0.91-1) after induction ipi+nivo then chemoRT in cT2-4aN0-2 MIBC.

vs leading data

Novelty is IO induction layered onto bladder-preservation chemoRT; benchmark vs historic trimodality needs the missing N/design

Combined Curative Phase 2 trial Early signal

7 details 5 trials watching

Methods

🔍 Stage II/III (cT2-4aN0-2) MIBC; induction ipilimumab + nivolumab → chemoradiation, bladder-sparing intent
🔍 Dual checkpoint induction precedes CRT, deferring upfront radical cystectomy

Results

📊 2-yr bladder-intact EFS 78% (95% CI 0.67-0.9), the bladder-preservation endpoint
📊 2-yr OS 96% (95% CI 0.91-1)

Critique

⚠️ Single-arm: no randomised comparator vs cystectomy or CRT alone, so IO induction's added value can't be isolated
⚠️ RT dose, fractionation, target volume, and N not reported in source tweets
⚠️ 2-yr f/u short for preservation; salvage cystectomy rate and patterns of failure not reported in source

Open questions

Contribution of ipi+nivo induction vs chemoradiation alone

recruiting A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study Phase 1/2

n=50 · primary completion 2024-07 · chemoRT + nivo vs ipi+nivo arms isolate ipi

active Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC Phase 2

n=50 · primary completion 2025-09 · single-arm induction ipi+nivo then chemoRT in MIBC
Durability of bladder preservation beyond 2 years

active Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation Phase 2

n=71 · primary completion 2025-12 · toripalimab + chemoRT bladder-sparing MIBC

active Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations Phase 2

n=237 · primary completion 2027-02 · gem/cis bladder preservation, no cystectomy
Randomised benchmark vs radical cystectomy or standard trimodality

recruiting Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) Phase 3

n=390 · primary completion 2030-03 · phase 3 EV+pembro vs concurrent chemoRT

Sourced from @5_utr

📚 Sources · 🐦 1 tweet

‼️ INDIBLADE: stage II/III (cT2-4aN0-2) MIBC -> induction ipilimumab plus nivolumab -> CRT

2-year bladder-intact event-free survival is 78% (0.67−0.9) 🤩

2-year overall survival was 96% (0.91−1)

Lots of bladders can be potentially spared!https://t.co/LzTe72GYHD
— NonsparseOncologist (@5_utr) June 17, 2026

💧 Bladder

INDIBLADE

Bladder